A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).

Electra D Paskett Jennifer G Le-Rademacher Jill M OliveriHeshan LiuDrew K SeislerJeffrey A SloanJane M ArmerMichelle J NaughtonKaren HockMichael SchwartzGary UnzeitigMarianne MelnikLisa D YeeGini F FlemingJohn R TaylorCharles L Loprinzi

Published in: Cancer (2020)

Lymphedema incidence did not differ by intervention group at 18 months. Poor adherence in the LEAP group may have contributed. However, physical therapy may speed recovery of ROM. Further research is needed to effectively reduce the incidence and severity of lymphedema in patients who have breast cancer.

Keyphrases

end stage renal disease
newly diagnosed
risk factors
randomized controlled trial
ejection fraction
chronic kidney disease
polycystic ovary syndrome
type diabetes
metabolic syndrome
skeletal muscle
insulin resistance
young adults
weight loss